Oppenheimer Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $63.00

Keros Therapeutics (NASDAQ:KROS) had its price objective lowered by Oppenheimer from $102.00 to $63.00 in a research note released on Monday morning, MarketBeat Ratings reports. The firm currently has an outperform rating on the stock.

A number of other brokerages have also recently weighed in on KROS. Guggenheim cut Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday. Jefferies Financial Group assumed coverage on Keros Therapeutics in a research report on Tuesday, November 5th. They issued a “buy” rating for the company. Wedbush reissued an “outperform” rating and set a $84.00 price target on shares of Keros Therapeutics in a research report on Thursday, November 7th. Bank of America dropped their price objective on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a report on Thursday, September 12th. Finally, HC Wainwright reduced their target price on shares of Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $81.33.

Keros Therapeutics Price Performance

NASDAQ KROS opened at $17.13 on Monday. The stock has a market capitalization of $693.88 million, a P/E ratio of -3.29 and a beta of 1.20. The firm’s 50-day moving average is $56.64 and its two-hundred day moving average is $52.06. Keros Therapeutics has a 12 month low of $15.67 and a 12 month high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company had revenue of $0.39 million during the quarter. During the same quarter in the prior year, the company posted ($1.33) EPS. The business’s revenue was up 4750.0% on a year-over-year basis. As a group, analysts anticipate that Keros Therapeutics will post -5.26 EPS for the current year.

Institutional Investors Weigh In On Keros Therapeutics

Several institutional investors have recently modified their holdings of the company. KBC Group NV increased its holdings in Keros Therapeutics by 52.0% in the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after buying an additional 432 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Keros Therapeutics by 26.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after acquiring an additional 280 shares during the last quarter. Values First Advisors Inc. purchased a new position in shares of Keros Therapeutics in the 3rd quarter valued at about $89,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Keros Therapeutics during the 2nd quarter worth about $128,000. Finally, LMR Partners LLP acquired a new position in Keros Therapeutics in the third quarter valued at approximately $213,000. 71.56% of the stock is owned by hedge funds and other institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.